Other SGLT-2s in Development
The recent approval of Invokana is exciting, opening the door to a new class of medications that can help people to manage type 2 diabetes, but it was not exactly the only drug on that long road to approval. Take a look at other potential medications that are in various stages of trials and approvals that may join this newest class of oral medications.
Astellas Pharma – Ipragliflozin
- This drug has been filed for marketing approval in Japan and is in the process of completing phase III trials.
- Trials have shown its potential to significantly lower glycated hemoglobin levels (HbA1c) over time as compared to placebo.
Bi/Lilly – Empagliflozin
- This drug is in Phase III of clinical trial process involving over 14,500 patients. There will be a total of 12 clinical trials performed throughout several countries.
- It is said that the companies will present results of the studies at some point in 2013 or 2014.
Chugai (Roche) – Tofogliflozin Hydrate
- According to Chugai Pharma, as of November 2010, this drug is in Phase III of clinical trials.
Lexicon – LX4211
- This drug inhibits both SGLT1 and SGLT2, making it the first of its kind to be introduced in clinical development for diabetes.
- LX4211 will begin Phase III clinical studies in the middle of 2013.
Taisho Pharma – luseogliflozin
- This drug is currently in Phase III of clinical trials.
Bristol-Myers Squibb – Farxiga
- This is a once- daily oral treatment specifically geared toward type 2 diabetes, to be used in conjunction with exercise and a proper diet. This treatment is currently in clinical trials.
Reviewed by James A. Bennett 04/14.
- • Astellas. AVEO and Astellas announce postive findings from TIVO-1 superiority study of tivozanib in first line advanced RCC., http://www.astellas.com/en/corporate/news/pdf/121003_Eg_1.pdf. (PDF) (Accessed 4/11/13.)
- • Lexicon Pharmaceuticals. LX4211, http://www.lexgen.com/pipeline/lx4211.html. (Accessed 4/11/13.)
- • Chugai Pharma USA. Annual report, 2011. http://www.chugai-pharm.co.jp/hc/ss/downloads/eAR2011_12_09.pdf?blobheader=application%2Fpdf&blobheadername1=content-disposition&blobheadervalue1=inline%3Bfilename%3DeAR2011_12_09.pdf&blobwhere=1259656736395&ssbinary=true. (PDF) (Accessed 4/11/13.)
- • Theheart.org. FDA approves new diabetes drug, canagliflozin, despite CV concerns, http://www.theheart.org/article/1523789.do. (Accessed 4/11/13.)
- • Drug Discovery & Development Magazine. Lilly, BI submit empagliflozin to FDA, http://www.dddmag.com/news/2013/03/lilly-bi-submit-empagliflozin-fda. (Accessed 4/11/13.)
Stir-Fried Brown Rice Barbecue Chicken and Pineapple Sandwich PB & J Banana Splits Salad With Mustard Vinaigrette Spanish White Bean Stew Spicy Garlic Potatoes Low-Carb Old-Fashioned Oatmeal Raisin Cookies Collard Greens Lemon Soy Aioli Spicy Chicken Tomato Soup
Lows are really nothing new to me. In the past (almost) 22 years, I've experienced every variety of low blood sugar. Two seizures, multiple black outs, the "I'm fine" at 32, the nauseating 85, and everything in between. That certainly doesn't mean that I'm used to them or that each low doesn't feel like a new and treacherous journey. They still scare me. They still annoy me. And they still overrun my life at times. Since I've hit the gym and the calorie counting on an aggressive...